Astrocytoma, IDH-mutant, grade 3
MONDO:0956995An IDH-mutant anaplastic astrocytoma that is characterized by the presence of increased mitotic activity and anaplastic features.
2844 clinical trials for this condition and its sub-types, 16 tagged with Astrocytoma, IDH-mutant, grade 3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental drug combo targets brain cancer metabolism
Disease control OngoingThis early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Precision proton beams aim to shrink brain tumors with fewer side effects
Disease control OngoingThis study tests a precise type of radiation called proton therapy for people with slow-growing brain tumors (low-grade gliomas). The goal is to see if it can control tumor growth as well as standard radiation while causing fewer side effects by sparing healthy brain tissue. Abou…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC